

Title (en)
2-SUBSTITUTED-1-DEAZA PURINE DERIVATIVES WITH ADENOSINE RECEPTOR MODULATING ACTIVITY

Title (de)
2-SUBSTITUIERTE-1-DEAZA-PURINDERIVATE MIT ADENOSIN- REZEPTORMODULIERUNGSAKTIVITÄT

Title (fr)
DÉRIVÉS DE 1-DEAZA PURINE 2-SUBSTITUÉS À ACTIVITÉ MODULATRICE DU RECEPTEUR D'ADÉNOSINE

Publication
EP 1791841 A1 20070606 (EN)

Application
EP 05789581 A 20050907

Priority

- EP 2005054405 W 20050907
- EP 04104345 A 20040909
- US 60814504 P 20040909
- EP 05789581 A 20050907

Abstract (en)
[origin: WO2006027366A1] The present invention relates to 2-substituted-1 -deaza purine derivatives as adenosine receptor modulating agents, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said purine derivatives. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.

IPC 8 full level
C07D 471/04 (2006.01); **A61K 31/437** (2006.01); **A61P 9/00** (2006.01); **A61P 25/00** (2006.01)

CPC (source: EP)
A61P 3/10 (2017.12); **A61P 9/00** (2017.12); **A61P 9/04** (2017.12); **A61P 9/06** (2017.12); **A61P 9/10** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 19/10** (2017.12); **A61P 25/00** (2017.12); **A61P 25/08** (2017.12); **A61P 25/16** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 31/04** (2017.12); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/00** (2017.12); **C07D 471/04** (2013.01)

Citation (search report)
See references of WO 2006027366A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
HR

DOCDB simple family (publication)
WO 2006027366 A1 20060316; AR 050860 A1 20061129; CA 2579303 A1 20060316; EP 1791841 A1 20070606; TW 200616624 A 20060601

DOCDB simple family (application)
EP 2005054405 W 20050907; AR P050103719 A 20050906; CA 2579303 A 20050907; EP 05789581 A 20050907; TW 94130124 A 20050902